Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
A pipeline of unique candidates with the potential to transform the prevention and treatment of cancer and infectious diseases. Our AI-Immunology™ platform enables a high level of scalability, offering the potential to expand our portfolio to the benefit of patients worldwide.
At the forefront of biotechnological innovation, our cutting-edge research is dedicated to advancing vaccine immunotherapies to battle cancer and infectious diseases. With a wide range of multidisciplinary capabilities, our research allows for continuous iterative learning loops which accelerates the development of transformative treatments and significantly enhance the value of our platform.
Since 2021, Evaxion has been listed on the Nasdaq Capital Market exchange (ticker code: EVAX). Here you can find all of the latest Evaxion investor insights: our results, upcoming events and news, important shareholder updates and much more.
We believe collaborating with leading and like-minded partners will create the best-in-class vaccines for patients. Our business model is geared toward a multi-partner approach focused around single or multiple vaccine target discovery, drug design and development agreements
Stay informed with Evaxion’s latest press releases, events, scientific materials, and media resources.
Evaxion > News & resources
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Evaxion announces business update and second quarter 2026 financial results
AUG 31, 2026
Scientific posters
The European Conference on Computational Biology 2026 (ECCB)
AI-Immunology™ designs shared ERV-derived therapeutic vaccine for acute myeloid leukemia
JUL 13, 2026
International Herpesvirus Workshop (IHW) 2026
AI-driven multi-antigen vaccine design to address CMV infection, latency and immune evasion
JUN 11, 2026
European Hematology Association (EHA) 2026
Preclinical characterization of EVX-04, an AI-designed off-the-shelf cancer vaccine targeting endogenous retroviral antigens in acute myeloid leukemia
MAY 13, 2026
CIMT 2026
Immune signatures associated with clinical response to the personalized neoantigen vaccine EVX-01 and pembrolizumab in advanced melanoma
MAY 4, 2026
Vaccinology: A New Era in Immune-Driven Vaccine Design
AI-Immunology™: An Artificial Intelligence Platform Advancing Vaccine Development Across AMR Bacteria and Viral Pathogens
APR 22, 2026
AACR 2026
Endogenous Retrovirus–Derived Neoantigens Enable a Personalized Cancer Vaccine Strategy for Glioblastoma
